Black Diamond Therapeutics Q2 net loss narrows as costs drop

Reuters

2025/08/07

<a href="https://laohu8.com/S/BDIMF">Black Diamond</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> <a href="https://laohu8.com/S/QTWO">Q2</a> net loss narrows as costs drop

Overview

Black Diamond Q2 net loss narrows to $10.6 mln from $19.9 mln yr/yr
Exploring partnerships to advance silevertinib development in NSCLC and GBM

Outlook

Black Diamond expects Q4 2025 data release for silevertinib Phase 2 trial
Company plans FDA meeting in 1H 2026 for silevertinib NSCLC path
Black Diamond exploring partnerships for silevertinib pivotal development
Company sees cash funding operations into Q4 2027

Result Drivers

EXPENSE REDUCTION - Reduced R&D and G&A expenses due to workforce efficiencies and restructuring

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Net Income		-$10.56 mln
Q2 Basic EPS		-$0.19
Q2 Cash & Investments		$142.80 mln
Q2 Income From Operations		-$13.42 mln
Q2 Operating Expenses		$13.42 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $11.00, about 75.5% above its August 6 closing price of $2.69

Press Release: ID:nGNX3VLXy8

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557568220"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557568220\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557568220?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557568220","market":"us","top_or_hot":-1,"title":"Black Diamond Therapeutics Q2 net loss narrows as costs drop","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/BDIMF\">Black Diamond</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss narrows as costs drop</title></head><body><p><span>Overview</span></p><ul><li><p><a href=\"https://laohu8.com/S/BDTX\">Black Diamond</a> Q2 net loss narrows to $10.6 mln from $19.9 mln yr/yr</p></li><li><p>Exploring partnerships to advance silevertinib development in NSCLC and GBM</p></li></ul><p><span>Outlook</span></p><ul><li><p>Black Diamond expects Q4 2025 data release for silevertinib Phase 2 trial</p></li><li><p>Company plans FDA meeting in 1H 2026 for silevertinib NSCLC path</p></li><li><p>Black Diamond exploring partnerships for silevertinib pivotal development</p></li><li><p>Company sees cash funding operations into Q4 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>EXPENSE REDUCTION - Reduced R&amp;D and G&amp;A expenses due to workforce efficiencies and restructuring</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$10.56 mln</p></td><td></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-$0.19</p></td><td></td></tr><tr><td><p>Q2 Cash &amp; Investments</p></td><td></td><td><p>$142.80 mln</p></td><td></td></tr><tr><td><p>Q2 Income From Operations</p></td><td></td><td><p>-$13.42 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$13.42 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $11.00, about 75.5% above its August 6 closing price of $2.69</p></li></ul><p>Press Release: <span>ID:nGNX3VLXy8</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Black Diamond Therapeutics Q2 net loss narrows as costs drop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlack Diamond Therapeutics Q2 net loss narrows as costs drop\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-07 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/BDIMF\">Black Diamond</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss narrows as costs drop</title></head><body><p><span>Overview</span></p><ul><li><p><a href=\"https://laohu8.com/S/BDTX\">Black Diamond</a> Q2 net loss narrows to $10.6 mln from $19.9 mln yr/yr</p></li><li><p>Exploring partnerships to advance silevertinib development in NSCLC and GBM</p></li></ul><p><span>Outlook</span></p><ul><li><p>Black Diamond expects Q4 2025 data release for silevertinib Phase 2 trial</p></li><li><p>Company plans FDA meeting in 1H 2026 for silevertinib NSCLC path</p></li><li><p>Black Diamond exploring partnerships for silevertinib pivotal development</p></li><li><p>Company sees cash funding operations into Q4 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>EXPENSE REDUCTION - Reduced R&amp;D and G&amp;A expenses due to workforce efficiencies and restructuring</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$10.56 mln</p></td><td></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-$0.19</p></td><td></td></tr><tr><td><p>Q2 Cash &amp; Investments</p></td><td></td><td><p>$142.80 mln</p></td><td></td></tr><tr><td><p>Q2 Income From Operations</p></td><td></td><td><p>-$13.42 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$13.42 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $11.00, about 75.5% above its August 6 closing price of $2.69</p></li></ul><p>Press Release: <span>ID:nGNX3VLXy8</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLXFFC28F:1","article_id":"2557568220","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557568220","pubTimestamp":1754568175,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Black Diamond Therapeutics Q2 net loss narrows as costs dropOverviewBlack Diamond Q2 net loss narrows to $10.6 mln from $19.9 mln yr/yrExploring partnerships to advance silevertinib development in NSC","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BDTX":"Black Diamond Therapeutics, Inc."},"translate_title":"随着成本下降，Black Diamond Therapeutics第二季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDTX":0.9},"content_text":"Black Diamond Therapeutics Q2 net loss narrows as costs dropOverviewBlack Diamond Q2 net loss narrows to $10.6 mln from $19.9 mln yr/yrExploring partnerships to advance silevertinib development in NSCLC and GBMOutlookBlack Diamond expects Q4 2025 data release for silevertinib Phase 2 trialCompany plans FDA meeting in 1H 2026 for silevertinib NSCLC pathBlack Diamond exploring partnerships for silevertinib pivotal developmentCompany sees cash funding operations into Q4 2027Result DriversEXPENSE REDUCTION - Reduced R&D and G&A expenses due to workforce efficiencies and restructuringKey DetailsMetricBeat/MissActualConsensus EstimateQ2 Net Income-$10.56 mlnQ2 Basic EPS-$0.19Q2 Cash & Investments$142.80 mlnQ2 Income From Operations-$13.42 mlnQ2 Operating Expenses$13.42 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $11.00, about 75.5% above its August 6 closing price of $2.69Press Release: ID:nGNX3VLXy8(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}